Repligen Beats Q2 Estimates, Raises 2026 Guidance on Strong Bioprocessing Demand
Repligen posts $204M Q2 revenue (+12%), adjusted EPS of $0.54 beating estimates. Raises FY26 organic growth to 10.5%-13.5% and EPS to $2.03-$2.09.
/ 58 items
#XY Earnings Movers↓
Summit Therapeutics Warns of Cash Crunch That Could Threaten Operations Despite Strong Cancer Drug Progress
Summit Therapeutics says its cash won’t cover operations for a year, raising going-concern concerns. Shares fall as the company seeks funding while advancing ivonescimab development.
Tenet Healthcare Shares Surge After Strong Q2 Beat and Raised 2026 Outlook
Tenet beat expectations, raised forecasts, boosted profits and cash flow, and saw its stock jump sharply on strong hospital and outpatient performance.
Novartis Beats Q2 2026 Expectations as New Drugs Offset Generic Pressure
Novartis reported strong Q2 2026 results with $14.41B sales and a core profit beat, driven by Kisqali (+43%) and Scemblix. Full-year guidance reaffirmed despite Entresto patent cliff.
Intuitive Surgical Shares Plunge as Da Vinci Procedure Growth Slows Sharply
GLP-1 drugs and insurance uncertainty weigh on demand.
Abbott Raises 2026 Outlook After Solid Q2 Beat Driven by Diagnostics and Devices
Abbott delivered robust Q2 2026 earnings driven by 42% growth in its Diagnostics segment, led by strong Cologuard adoption.